Department of Biology, New York University, New York, New York, United States of America.
Department of Biology, Sacred Heart University, Fairfield, Connecticut, United States of America.
PLoS One. 2021 Aug 4;16(8):e0255417. doi: 10.1371/journal.pone.0255417. eCollection 2021.
Due to the sheer number of COVID-19 (coronavirus disease 2019) cases there is a need for increased world-wide SARS-CoV-2 testing capability that is both efficient and effective. Having open and easy access to detailed information about these tests, their sensitivity, the types of samples they use, etc. would be highly useful to ensure their reproducibility, to help clients compare and decide which tests would be best suited for their applications, and to avoid costs of reinventing similar or identical tests. Additionally, this resource would provide a means of comparing the many innovative diagnostic tools that are currently being developed in order to provide a foundation of technologies and methods for the rapid development and deployment of tests for future emerging diseases. Such a resource might thus help to avert the delays in testing and screening that was observed in the early stages of the pandemic and plausibly led to more COVID-19-related deaths than necessary. We aim to address these needs via a relational database containing standardized ontology and curated data about COVID-19 diagnostic tests that have been granted Emergency Use Authorizations (EUAs) by the FDA (US Food and Drug Administration). Simple queries of this actively growing database demonstrate considerable variation among these tests with respect to sensitivity (limits of detection, LoD), controls and targets used, criteria used for calling results, sample types, reagents and instruments, and quality and amount of information provided.
由于 COVID-19(冠状病毒病 2019)病例数量庞大,因此需要提高全球 SARS-CoV-2 检测能力,这需要兼具高效和有效。详细了解这些测试的详细信息,包括其敏感性、使用的样本类型等,对于确保其可重复性、帮助客户比较并决定哪些测试最适合他们的应用以及避免重复开发类似或相同测试的成本都非常有用。此外,该资源还将提供一种比较目前正在开发的许多创新诊断工具的方法,以便为未来新兴疾病的快速开发和部署测试提供技术和方法基础。这样的资源可能有助于避免在大流行早期观察到的测试和筛选延迟,这种延迟可能导致 COVID-19 相关死亡人数超过必要人数。我们旨在通过一个包含标准化本体论和经 FDA(美国食品和药物管理局)授予紧急使用授权 (EUA) 的 COVID-19 诊断测试的经过精心整理的数据的关系数据库来满足这些需求。对这个不断增长的数据库进行简单查询,即可显示这些测试在敏感性(检测限,LoD)、使用的对照和靶标、用于判断结果的标准、样本类型、试剂和仪器以及提供的质量和信息量等方面存在很大差异。